Peru – FIU | Yale

 

Location
Lima, Peru

Site Institutions
CRONICAS, Universidad Peruana Cayetano Heredia, Lima, Peru - FIU
Asociación Civil Impacta Salud y Educación - Yale

US Institution
Florida International University
Yale University School of Public Helth

 

FIU Research Focus: Chronic diseases, hypertension, nutrition, obesity

yALE RESEARCH FOCUS: HIV PREVENTION AND TREATMENT AMONG MEN WHO HAVE SEX WITH MEN (MSM)

Site Description | FIU
CRONICAS, the Center for Excelence in Chronic Disease Research at the Universidad Peruana Cayetano Heredia is a research group with considerable international research collaboration and training experience. Current research and completed projects at CRONICAS have focused on the burden of non-communicable diseases in the Peruvian population. Ongoing and completed projects have been funded through the NIH and the Wellcome Trust and have focused on issues such as diabetes, hypertension, mental health, disparities within the physically disabled population, the double burden of chronic disease and neglected tropical diseases, childhood obesity, and telemedicine. Potential research areas for Fogarty Global Health Fellows at CRONICAS include any projects aimed at reducing the burden of non-communicable diseases within the Peruvian population. The current research collaboration with FIU examines the role of social networks in obesity and obesity related attitudes in a population in Tumbes, Peru. GHES Fellow Kathleen McInvale, PhD, is conducting a social network study as an ancillary study to a larger NIH funded project examining the effectiveness of a salt substitute in reducing blood pressure. More than 20 researchers specializing in chronic non-communicable diseases have been trained through the center since its founding in 2009. The mission of the center is to develop young researchers in collaboration with national and international institutions.

Site Description | Yale
The training site will include Impacta Peru, the country’s largest HIV/AIDS service organization and research institute that is a member of the AIDS Clinical Trials Group (ACTG), HIV Prevention Trials Network (HPTN) and the HIV Vaccine Trials Network (HVTN). They have ongoing relationships with many of the country’s largest NGOs that provide HIV and TB prevention and treatment in Peru, the Ministry of Health and Cayetano Herredia School of Medicine. Drs. Altice and Sanchez have collaborated together since 2010 in these sites, which have served as training sites for numerous pre- and post-doctoral fellows. The team has conducted bio-behavioral surveillance studies, health services research, interventions that promote HIV testing, linkage and retention in care and other health outcomes. Specifically, this team has been exploring the impact of alcohol use disorders and drug use among men who have sex with men (MSM) because Peru is experiencing a concentrated epidemic among this group. Some of the interventions being considered include mHealth interventions delivered using an app.  New studies are examining the risk of TB treatment adherence and completion among those with and without alcohol and drug use disorders. Primary and secondary prevention studies are underway, including treatment as prevention and adherence studies using medication-assisted therapy (e.g., naltrexone) and behavioral interventions.

In addition, Impacta has relationships with many other universities including University of Washington and UCLA, where there are many active research projects. Drs. Altice and Sanchez collaborate on two active R01 grants from the NIDA and NIAAA and are writing new grants to expand some of this work to TB. The primary R01 is to expand HIV testing and to examine the impact of acute HIV infection (AHI) on ongoing HIV transmission among MSM. We will conduct network analyses and study linkage and retention in care after acute diagnosis as well as to examine the impact of “immediate” antiretroviral therapy on reducing onward HIV transmission. A second aim of this study is to conduct a RCT using extended-release naltrexone (XR-NTX) among MSM with alcohol use disorders who are newly diagnosed and to examine the impact of XR-NTX on retention in care, adherence, viral suppression and HIV transmission. We are also examining the impact of alcohol, drugs and neurocognitive impairment on HIV treatment outcomes as well as exploring mobile health technologies on improving HIV treatment outcomes. The second R01 is a comparative effectiveness trial comparing a pharmacotherapy versus a behavioral intervention for alcohol use disorders among HIV-infected MSM.

GHES fellowships conducted at these sites:
 

FIU US Mentor

  Purnima Madhivanan, MD, MPH, PhD  Associate Professor Robert Stempel College of Public Health & Social Work  Email

Purnima Madhivanan, MD, MPH, PhD
Associate Professor
Robert Stempel College of Public Health & Social Work
Email

FIU Local Mentor

  Antonio Bernabé-Ortiz, MD, MPH  Research Professor, CRONICAS, Universidad Peruana Cayetano Heredia  Email

Antonio Bernabé-Ortiz, MD, MPH
Research Professor, CRONICAS, Universidad Peruana Cayetano Heredia
Email

Yale US Mentor

   Frederick Altice, MD   Professor of Medicine (Infectious Diseases) and of Epidemiology (Microbial Diseases); Director, Clinical and Community Research; Director, HIV in Prisons Program; Director, Community Health Care Van; Icon Professor of Medicine, University of Malaya-Centre of Excellence for Research in AIDS (CERiA); Professor of Epidemiology and Public Health, Division of Epidemiology of Microbial Diseases  Website   Email

Frederick Altice, MD
Professor of Medicine (Infectious Diseases) and of Epidemiology (Microbial Diseases); Director, Clinical and Community Research; Director, HIV in Prisons Program; Director, Community Health Care Van; Icon Professor of Medicine, University of Malaya-Centre of Excellence for Research in AIDS (CERiA); Professor of Epidemiology and Public Health, Division of Epidemiology of Microbial Diseases
Website
Email

Yale Local Mentor

  Jorge Sanchez, MD, MPH  Principal Investigator, AIDS Clinical Trial Group  Email

Jorge Sanchez, MD, MPH
Principal Investigator, AIDS Clinical Trial Group
Email